Last $1.86 USD
Change Today -0.1099 / -5.58%
Volume 18.4K
DSKX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

ds healthcare group inc (DSKX) Snapshot

Open
$1.96
Previous Close
$1.97
Day High
$1.98
Day Low
$1.86
52 Week High
01/14/14 - $2.74
52 Week Low
07/29/13 - $1.41
Market Cap
29.9M
Average Volume 10 Days
12.8K
EPS TTM
$-0.23
Shares Outstanding
16.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DS HEALTHCARE GROUP INC (DSKX)

Related News

No related news articles were found.

ds healthcare group inc (DSKX) Related Businessweek News

No Related Businessweek News Found

ds healthcare group inc (DSKX) Details

DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products include Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, as well as Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia. The company’s skin care products comprise Hydroviton, a skin cleanser for oily and acne prone skin; Keramene, which is used to suppress hair growth and soften remaining hair strands; Oligo.DX, a cream to enhance the appearance of cellulite from women’s thighs, hips, and buttocks; and Trioxil, an acne cream. Its personal care products consist of Nirena, an intimate feminine care cleanser; and Revita.EPS, a product based on advanced bio-peptides that are designed to grow and enhance the length and girth of eyelash hair. DS Healthcare Group, Inc. markets and sells its products under the DS Laboratories, Polaris Labs, Sigma Skin, and Pure Guild brands through salons, spas, department stores, specialty retailers, and distributors. The company was formerly known as Divine Skin, Inc. and changed its name to DS Healthcare Group, Inc. in November 2012. DS Healthcare Group, Inc. is headquartered in Pompano Beach, Florida.

ds healthcare group inc (DSKX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $169.9K
Consultant
Total Annual Compensation: $102.0K
Compensation as of Fiscal Year 2013.

ds healthcare group inc (DSKX) Key Developments

DS Healthcare Group, Inc. Signs Distribution Agreement with Drogaria Iguatemi

DS Healthcare Group, Inc. announced it has signed a distribution agreement with Drogaria Iguatemi. This marks the second distribution agreement signed by DS Healthcare in Brazil's $43 billion beauty industry. The company's products are experiencing robust sales growth in the Rio de Janeiro metropolitan area, as well as through DS Healthcare's Brazilian e-commerce site. Drogaria Iguatemi has Sao Paulo's most affluent chain of pharmacies. Selecting to carry only the most important brands in medicine, cosmetics, derma-cosmetics and skin care products in the world. Drogaria Igautemi has already begun retailing DS Healthcare's products.

DS Healthcare Group, Inc. Announces Audited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2013; Reports Impairment of Intangible Assets; Plans to Begin Clinical Development of its Pharmaceutical Hair Loss Product in 2014

DS Healthcare Group, Inc. announced audited consolidated financial results for the fourth quarter and year ended December 31, 2013. For the year, the company's net revenues increased to a record $13,651,661, up $2,427,237 or 22%, from $11,224,424 in 2012. Revenue increase was driven by the company's Mexican subsidiary acquired at the end of 2012 and the fulfillment of backlog orders from the fourth quarter of 2012. The company's Revita and Revita COR hair re-growth stimulating shampoos and conditioners were the primary contributors to revenues, representing 40% of total sales. The company's net loss narrowed by 11% to $3,225,289 or $0.25 per basic and diluted share in 2013 from $3,623,109 or $0.33 per basic and diluted share in 2012, driven by record revenues and higher gross margins, partially offset by higher general and administrative costs. Operating loss was $3,292,765 compared to $3,611,243 reported a year ago. Loss before income taxes was $3,129,257 compared to $3,623,110 reported a year ago. Net loss attributable to shareholders was $3,209,431 compared to $3,606,744 reported a year ago. Net cash used in operating activities was $980,057 against $1,810,173 reported a year ago. Purchase of furniture and equipment was $46,794 against $160,753 reported a year ago. Adjusted LBITDA was $1,169,338 compared to $1,848,730 reported a year ago. Revenue growth was driven primarily by sales of its Revita Shampoo and Spectral treatment lines that are recognized around the world for their efficacy in hair re-growth. For the quarter, the company's net revenues were $3,058,626, an 11% increase over net revenues of $2,768,573 in the fourth quarter of 2012. The revenue increase was driven by increased demand for DS Healthcare's products and the acquisition of the company's Mexican subsidiary. The company's net loss narrowed by 67% to $944,861 or $0.07 per basic and diluted share from $2,774,324 or $0.23 per basic and diluted share in fourth quarter of 2012, driven by increased sales, improved gross profit margins and an overall restructuring of expenses. Adjusted LBITDA was $110,189 compared to $1,893,901 reported a year ago. For the quarter, the company reported impairment of intangible assets of $88,910. During 2014, the company plans to begin the clinical development of its pharmaceutical hair loss product, which it believes addresses a $10 billion market in need of a product that works. If approved, the company believes its product would be only the third prescription grade hair loss product and the second topical prescription grade hair loss product to receive FDA approval in the U.S.

DS Healthcare Group, Inc. announced delayed annual 10-K filing

On 04/01/2014, DS Healthcare Group, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKX:US $1.86 USD -0.1099

DSKX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DSKX.
View Industry Companies
 

Industry Analysis

DSKX

Industry Average

Valuation DSKX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DS HEALTHCARE GROUP INC, please visit www.dslaboratories.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.